Detalhe da pesquisa
1.
A multicenter real-world study of bevacizumab in heavily pretreated malignant gliomas: clinical benefit is a plausible end point?
Future Oncol
; 15(15): 1717-1727, 2019 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-30977687